Apropos for today.
No. There is only one me.
I sold, and I probably won't be back until the P2B trial has actually enrolled its first patient.
I agree, but the most important data (P2B) won't be released until 2016.
Monotherapy data won't move the needle much anymore. Maybe a year ago, but not now. You have to adjust to changing conditions.
Yes, but it's his fiduciary responsibility not to mislead investors by making invalid/improper statements in person or by tweeting them. One thing you learn to NEVER do is to set false expectations. Especially someone in his position.
His uncle needs to give him a tongue lashing.
I sold because Punit potentially lied to some investors. I want to understand what others think of him as a CEO.
By the way, I love the science, if we can ever get the P2B trial started.
It's possible, Wait, but to me it just doesn't make for a compelling investment case at this point.
We've had data releases in the past. Why are we sitting at 0.35 now? Because those data releases were not SIGNIFICANT to the PPS in a SUSTAINABLE way. And P1 monotherapy trial data will not get it done anymore, IMHO. Only combinatorial trial data will.
Successful P2B data is the only SIGNIFICANT data which can move the PPS higher in a SUSTAINABLE way.
Wait--well said. There is some "interesting" trial data which could be released later this year.
But one needs to differentiate between altruism (in a pure scientific discovery sense) versus data releases which will move the PPS in a SUSTAINED and meaningful way.
I see nothing that fits that criteria until sometime in 2016.
I know lots of people who sold.
I personally sold 100K shares today and moved into stocks where I can trust the CEO.
How many of you are confident in your CEO?
Note: I didn't say "confident in your science."
I'll re-phrase. How many of you are confident that your CEO can take the science to the next level in an acceptable time-frame? And why? (Either way.)
Guti--your last statement is the most telling and true:
"The initiation of trials will only raise the price momentarily but results will take the company to a new level."
In short, there is NOTHING in the short-term which will lead to SUSTAINABLE shareholder value. I repeat, nothing.
Meaningful data which will have a LASTING effect on the PPS is now not due out until sometime in 2016, at the earliest.
And by that time one of the biggest run-ups in biotech history may be behind us. The opportunity costs are HUGE holding on to this stock, wouldn't you agree? Or are you not invested elsewhere?
Guti--you don't see those cancer patients either. Being a bit presumptuous with your rhetorical statement? Frankly, I'd be disappointed to hear about something which could potentially be helpful to my condition being delayed, again?
I've read many of your previous informative posts. Surely you've got more than that?
Low volume? I beg to differ Fur. What ticker are you looking at? Scottrade shows volume already at 160% of daily normal. With two hours to go.
Yes. We're frustrated that the most important trial in the company's history has been pushed back (again).
We're also frustrated by the lack of transparency, ambiguity, and clarity in Punit's forward-looking statements. In fact, one could argue that he actually personally lied to some investors about the start of the P2B trial.
Need I say more?